B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PI4KB

MOLECULAR TARGET

phosphatidylinositol 4-kinase beta

UniProt: Q9UBF8NCBI Gene: 529817 compounds

PI4KB (phosphatidylinositol 4-kinase beta) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PI4KB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1lapatinib4.84126
2ruxolitinib4.2368
3pi 1034.1764
4pazopanib3.6939
5tae 6843.4330
6fedratinib3.4029
7buparlisib3.4029
8lestaurtinib3.0420
9r 4062.8316
10plx 47202.7114
11torin12.4010
12azd 64822.309
13bimiralisib2.309
14tg100 1152.087
15rg 5472.087
16Wortmannin1.393
17torin 11.102

About PI4KB as a Drug Target

PI4KB (phosphatidylinositol 4-kinase beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented PI4KB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PI4KB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.